Understanding the Type 1.5 Diabetes Problem
Most people know about type 1 and type 2 diabetes. But there's a third category that creates massive diagnostic confusion in clinical practice: LADA — latent autoimmune diabetes in adults. It's been called "type 1.5," and that name captures the essential problem: LADA looks like type 2 at first, but behaves like type 1 underneath.1
Every year, thousands of adults are misdiagnosed with type 2 diabetes when they actually have LADA: it accounts for an estimated 2–12% of adult-onset diabetes,1 and over 40% of people who develop type 1 diabetes after age 30 are first treated as having type 2.2 This isn't a minor labeling issue. It can lead to treatment that may speed beta cell loss.3 Understanding how to tell them apart using blood tests is critical for anyone diagnosed with diabetes in adulthood.
What LADA Actually Is
LADA is an autoimmune disease where the pancreas is slowly destroyed by the body's own immune system. The difference from classical type 1 diabetes is timing and speed: type 1 classically develops in children and teenagers (though it can start at any age) and strikes rapidly over weeks to months.4 LADA develops in adults (usually after age 30) and progresses over months to years.1
The hallmark of LADA is the presence of autoantibodies — immune proteins aimed at parts of the insulin-producing beta cells in the pancreas. The most common is glutamic acid decarboxylase (GAD65) antibody, found in about 90% of antibody-positive adults with autoimmune diabetes.5 Other relevant antibodies include islet antigen 2 (IA-2) and zinc transporter 8 (ZnT8).
Key insight: LADA is fundamentally autoimmune, meaning the beta cell failure is driven mainly by immune attack rather than insulin resistance. This distinction is everything for treatment strategy.
Early in LADA, blood glucose may be only mildly elevated, and patients often appear metabolically healthier than people with type 2 — they tend to be leaner, with better blood pressure and lipids.1 This creates the perfect storm for misdiagnosis: a lean adult with slightly elevated glucose gets labeled "type 2" when the underlying mechanism is actually autoimmune destruction.
Why LADA Gets Misdiagnosed as Type 2
Type 2 diabetes is far more common than LADA — roughly 90-95% of all diabetes cases are type 2.6 Clinically, this creates a base-rate bias: when you see an adult with elevated fasting glucose, the statistical likelihood that it's type 2 is very high.
LADA also usually lacks the dramatic onset of type 1 diabetes: by definition, people with LADA don't need insulin for at least the first 6 months after diagnosis.1 Instead, patients might be diagnosed after a routine blood test or because they're noticing gradual fatigue. This gradual presentation looks "type 2-like," and without specific antibody testing, the diagnosis defaults to type 2.5
The consequences are serious. If a LADA patient is treated as type 2, they typically start on metformin and possibly sulfonylureas (drugs that force the beta cells to produce more insulin). For type 2 patients, sulfonylureas can make sense — their beta cells still have reserve to push. But for LADA patients, sulfonylureas are not recommended: in trials they led to earlier insulin dependence, possibly by wearing out already-failing beta cells.31
Key insight: Treating LADA as type 2 isn't just a labeling error — it can lead to treatment that may speed disease progression.
The Blood Tests That Tell Them Apart
Three classes of blood tests distinguish LADA from type 2:
Autoantibody Testing
In a European study of more than 6,000 adults with recently diagnosed diabetes, about 90% of antibody-positive patients had GAD65 antibodies, and other antibodies alone were rare;5 in an Italian cohort, ZnT8 antibodies turned up in about 19% of adults with autoimmune diabetes but only 1.4% of antibody-negative type 2.7
| Antibody | LADA Prevalence | Significance |
|---|---|---|
| GAD65 | ~90% | Most common; present alone or with other antibodies |
| IA-2 | Less common | Often found alongside GAD65 |
| ZnT8 | ~19% | Less common, but highly specific when present |
| Any autoantibody positive | Required for diagnosis | Defines LADA in an adult who didn't need insulin at first |
If any of these antibodies is positive in an adult over 30 who didn't need insulin for the first 6 months, LADA is the diagnosis1 — though low-level GAD antibodies can show up in adults without autoimmune diabetes, so a borderline result needs clinical context.2 The key is that these tests must be ordered — they're not part of standard diabetes screening.4 Many primary care clinicians don't think to order them.
C-Peptide Testing
C-peptide is a biomarker of endogenous (your own body's) insulin production. It's released in equimolar amounts with insulin, so it's a clean measure of how much insulin your pancreas is still making.8
In type 2 diabetes, C-peptide is typically normal or high because the pancreas is compensating for insulin resistance by producing more insulin; persistently high levels strongly suggest type 2.2
In LADA, C-peptide starts out relatively normal but declines over time as beta cells are destroyed — more slowly than in classic type 1, but faster than in type 2.1
Testing C-peptide at baseline and then repeating it — at least every 6 months when levels are borderline — can reveal the trajectory:1
- Stable or rising C-peptide = likely type 2
- Declining C-peptide + positive autoantibody = LADA
Metabolic Markers
Insulin resistance markers (HOMA-IR, fasting insulin) help too. LADA patients typically have less insulin resistance (lower HOMA-IR) than people with antibody-negative type 2 — their problem isn't that their cells ignore insulin, it's that they don't have enough insulin because their beta cells are dying.1 Type 2 patients, by contrast, have high HOMA-IR and elevated fasting insulin (in the early stages).
Typical LADA Presentation
A realistic LADA case: A 42-year-old woman, BMI 23, comes in for a physical. Her fasting glucose is 118 mg/dL, A1C is 7.2%. She's not overweight, exercises regularly, has good lipids. Her doctor prescribes metformin and tells her it's "type 2." Run your own number with the free A1C to blood sugar calculator.
Six months later, despite good diet and exercise, her fasting glucose is now 145, and she's developed fatigue. She's switched to a sulfonylurea. A year later, she's now on insulin because her glucose control has deteriorated.
The actual timeline: Her immune system was destroying beta cells the whole time. The metformin and sulfonylurea didn't address the problem — they just masked it while beta cells continued to die. If she'd been diagnosed with LADA immediately and started on insulin, she might have (the evidence is still limited):3
- Preserved more remaining beta cell function
- Achieved better glucose control earlier
- Had a clearer prognosis and treatment roadmap
Treatment Differences: Why They Matter
LADA and type 2 require fundamentally different approaches.
Type 2 Diabetes Treatment
- Start with lifestyle + metformin
- Add other agents (GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors) — GLP-1 agonists and SGLT2 inhibitors are favored when heart or kidney disease is present
- Use sulfonylureas/meglitinides as intermediate agents
- Insulin usually comes later, as many people eventually need it — or early if glucose is very high (300 mg/dL or more)9
LADA Diabetes Treatment
- C-peptide guides the plan: below 0.3 nmol/L, insulin as in type 1; between 0.3 and 0.7, a modified type 2 approach, often with insulin; above 0.7, a modified type 2 approach with C-peptide monitoring1
- Avoid sulfonylureas — they may hasten beta cell failure3
- GLP-1 agonists can improve glucose control, but help less once C-peptide is very low
- Insulin is effective and safe; metformin is recommended for many, especially those with obesity1
- Evidence that GLP-1 agonists or DPP-4 inhibitors preserve beta cell function is still preliminary1
The reason this matters: beta cells lost to autoimmune destruction don't come back. Every month of inappropriate treatment that accelerates their death is permanent damage. A LADA patient diagnosed early and treated correctly may maintain some insulin production for years. A LADA patient treated as type 2 may lose that faster: in trials, insulin preserved stimulated C-peptide better than sulfonylureas.3
Key insight: In LADA, insulin is not a failure — it's an effective, safe treatment, and early use may help protect remaining beta cells, though that benefit is still unproven.1
How to Get Diagnosed Correctly
If you've been diagnosed with type 2 diabetes, especially if you're:
- Lean or normal weight10
- Diagnosed after age 30
- Not strongly insulin-resistant (normal blood pressure, lipids, no NAFLD)
- Failing to achieve good control on standard type 2 medications
...ask your doctor to order:
- GAD65 antibody
- IA-2 antibody
- ZnT8 antibody
- C-peptide, with a glucose measured at the same time
Guidelines suggest GAD65 first, then IA-2 and/or ZnT8 if it is negative.2
If any autoantibody is positive, you likely have LADA (a low-level GAD result may need confirming).4 Request referral to an endocrinologist experienced with autoimmune diabetes. Your treatment strategy needs to change.
The Broader Metabolic Picture
Understanding your diabetes type isn't just about which medication to take — it's about predicting your disease trajectory and managing your health accordingly.
LADA patients need to:
- Monitor beta cell function (C-peptide, at least every 6 months when levels are borderline)1
- Screen for other autoimmune conditions (thyroid disease, celiac disease, pernicious anemia)2
- Start insulin earlier, not later — in UKPDS, most younger adults with GAD antibodies needed insulin within 6 years11
- Be aggressive about glucose control
- Discuss newer therapies with care — GLP-1 agonists can help glucose control, while SGLT2 inhibitors need monitoring for ketoacidosis when C-peptide is low1
Type 2 patients have a different path — many can improve significantly with weight loss, exercise, and metabolic optimization.12 LADA patients, by contrast, are fighting an immune process that no treatment can yet reverse.
How Merios Helps
When you upload your blood test results to Merios, our platform analyzes metabolic and immunological markers to help you understand your diabetes type and treatment trajectory. We flag key differentiators like autoantibodies, C-peptide trends, and insulin resistance markers so you can have a clearer picture of what's actually happening in your body.
If you've been diagnosed with diabetes but you're unsure whether it's truly type 2 or LADA, getting comprehensive blood test analysis is the first step toward accurate diagnosis and appropriate treatment.
Upload your blood test to Merios →
This article is for educational purposes and should not replace medical advice. If you have been diagnosed with diabetes, work with your healthcare provider or endocrinologist to determine your diabetes type and develop an appropriate treatment plan. Blood test interpretation should always be done in clinical context.